Previous 10 | Next 10 |
home / stock / dsnky / dsnky news
At the ASCO meeting, BioNTech presented phase-1 clinical trial data for its mRNA-based vaccine for pancreatic ductal adenocarcinoma (PDAC), a common form of pancreatic cancer. AstraZeneca and Daiichi presented data for the Destiny-Breast04 trial, which tested Enhertu against chemother...
The 2022 American Society of Clinical Oncology Annual Meeting that begins June 3 is perhaps is the most eagerly anticipated medical meeting of the year. Thousands of abstracts and studies will be presented from pharma and biotech companies large and small. Some of the results are ea...
Takeda Pharmaceutical will be able to deliver stellar growth during the next decade. China and emerging markets will be a key driver of growth. The current share price is very undervalued considering the long term growth prospects. For further details see: Takeda Pharmac...
Daiichi Sankyo Company, Limited (DSKYF) Q4 2021 Results Conference Call April 27, 2022 03:30 AM ET Company Participants Hiroyuki Okuzawa - Head of Corporate Planning & Management Division, CFO Wataru Takasaki - Executive Officer, Head of R&D Division Sunao Manabe - Representative Dire...
The Food and Drug Administration (FDA) granted breakthrough therapy designation to AstraZeneca (NASDAQ:AZN) and Daiichi Sankyo's (OTCPK:DSKYF) (OTCPK:DSNKY) Enhertu to treat certain patients with breast cancer. The FDA status for Enhertu is to treat adult patients with unresect...
Japan has scrapped the acquisition of 40M doses of AstraZeneca's (NASDAQ:AZN) COVID vaccines, Reuters reported citing a health ministry official who spoke in the parliament. Japan had initially agreed to purchase 120M doses, with the majority made locally by Daiichi Sankyo (OTCPK:DSKYF) ...
Daiichi Sankyo Company, Limited (DSKYF) Q3 2022 Earnings Conference Call January 31, 2022 01:00 AM ET Company Participants Hiroyuki Okuzawa - Director, Executive Officer, Head of Corporate Planning & Management Division, CFO Wataru Takasaki - Executive Officer, Head of R&D Div. Confer...
Daiichi Sankyo (OTCPK:DSKYF) announces that the EMA has validated the Type II Variation application for trastuzumab deruxtecan, jointly developed by AstraZeneca (NASDAQ:AZN) for the treatment of adult patients with unresectable or metastatic HER2 positive breast cancer who have rece...
Daiichi Sankyo (OTCPK:DSKYF) announces that the first patient was dosed in the global DESTINY-Lung04 phase 3 trial evaluating the efficacy and safety of Enhertu (trastuzumab deruxtecan), a HER2 directed antibody drug conjugate (ADC) being jointly developed by AstraZeneca (NASDAQ:AZN), as a fi...
Daiichi Sankyo Company Limited (DSKYF) Q2 2022 Earnings Conference Call October 29, 2021 2:30 AM ET Company Participants Sunao Manabe - President, Group CEO & Representative Director Wataru Takasaki - Executive Officer and Head of R&D Division Conference Call Participants Kazuaki Hash...
News, Short Squeeze, Breakout and More Instantly...
Daiichi Sankyo Co Ltd Sponsored ADR Level 1 Company Name:
DSNKY Stock Symbol:
OTCMKTS Market:
Compugen to Receive Milestone Payment Triggered by Dosing of First Patient in the Second Phase 3 Trial Evaluating Rilvegostomig PR Newswire Phase 3 trial evaluating rilvegostomig as monotherapy and in combination with AstraZeneca and Daiichi Sankyo's datopotamab deruxtecan in ...
2023-10-31 10:15:00 ET Big pharmas have the resources to make big, multi-year moves that can reshape or even redefine their businesses. As you may know, Merck (NYSE: MRK) is one of the largest of the big pharmas, with a market capitalization of $262 billion, and it just made one of ...
Astellas, Eisai, Daiichi Sankyo and Takeda Agree to Collaborate to Reduce Environmental Burden in the Field of Pharmaceutical Packaging PR Newswire TOKYO and OSAKA, Japan , Dec. 21, 2022 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO:...